, Tracking Stock Market Picks
Enter Symbol:
Repros Therapeutics Inc. (RPRX) [hlAlert]

Strong Buy
up 70.21 %

Repros Therapeutics Inc. (RPRX) rated Strong Buy with price target $23 by Ascendiant Capital Markets

Posted on: Tuesday,  May 14, 2013  4:25 PM ET by Ascendiant Capital Markets

Ascendiant Capital Markets rated Strong Buy Repros Therapeutics Inc. (NASDAQ: RPRX) on 05/14/2013. Previously Ascendiant Capital Markets rated Strong Buy Repros Therapeutics Inc. (NASDAQ:
RPRX) on 04/10/2012., when the stock price was $4.23. Since then, Repros Therapeutics Inc. has gained 70.21% as of 01/14/2016's recent price of $7.20.
If you would have followed the previous Ascendiant Capital Markets's recommendation on RPRX, you would have gained 70.21% of your investment in 1374 days.

Repros Therapeutics Inc. (RPRX) is a development-stage biopharmaceutical company focused on the development of oral small molecule drugs for unmet medical needs. The Company's principal drug, Proellex, is a selective blocker of the progesterone receptor and is being developed for the treatment of uterine fibroids, anemia associated with excessive menstrual bleeding relating to uterine fibroids, or anemia associated with uterine fibroids and endometriosis. The second product candidate, Androxal, is a single isomer of clomiphene citrate and an orally active small molecule compound.

Ascendiant Capital Markets is led by George Santana, who has nearly twenty years of equity research experience in the United States and foreign markets. During his career, Mr. Santana has been recognized six consecutive times in the Institutional Investor magazine poll of top analysts.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/14/2013 4:25 PM Buy
17.28 23.00
as of 12/13/2013
1 Week up  0.82 %
1 Month up  17.59 %
3 Months down  -24.18 %
1 YTD up  9.07 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/15/2012 8:25 AM Buy
13.09 18.00
4/10/2012 8:25 AM Buy
4.23 6.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy